Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3β and NF-κB

Oncogene volume 23, pages 2465–2471 (2004)Cite this article

Abstract

A3 adenosine receptor (A3AR) activation with the specific agonist CF101 has been shown to inhibit the development of colon carcinoma growth in syngeneic and xenograft murine models. In the present study, we looked into the effect of CF101 on the molecular mechanisms involved in the inhibition of HCT-116 colon carcinoma in mice. In tumor lesions derived from CF101-treated mice, a decrease in the expression level of protein kinase A (PKA) and an increase in glycogen synthase kinase-3β (GSK-3β) was observed. This gave rise to downregulation of β-catenin and its transcriptional gene products cyclin D1 and c-Myc. Further mechanistic studies in vitro revealed that these responses were counteracted by the selective A3AR antagonist MRS 1523 and by the GSK-3β inhibitors lithium and SB216763, confirming that the observed effects were A3AR and GSK-3β mediated. CF101 downregulated PKB/Akt expression level, resulting in a decrease in the level and DNA-binding capacity of NF-κB, both in vivo and in vitro. Furthermore, the PKA and PKB/Akt inhibitors H89 and Worthmannin mimicked the effect of CF101, supporting their involvement in mediating the response to the agonist. This is the first demonstration that A3AR activation induces colon carcinoma growth inhibition via the modulation of the key proteins GSK-3β and NF-κB.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Alt JR, Cleveland JL, Hannink M and Diehl JA . (2000). Genes Dev., 14, 3102–3114.

  • Chana JS, Grover R, Tulley P, Lohrer H, Sanders R, Grobbelaar AO and Wilson GD . (2002). Br. J. Plast. Surg., 55, 623–627.

  • Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR and Mills GB . (2000). Proc. Natl. Acad. Sci. USA, 97, 11960–11965.

  • Ferkey DM and Kimelman D . (2000). Dev. Biol., 225, 471–479.

  • Fishman P, Bar-Yehuda S, Madi L and Cohn I . (2002a). Anti-cancer Drugs, 13, 1–8.

  • Fishman P, Bar-Yehuda S, Ohana G, Pathak S, Wasserman L, Barer F and Multani AS . (2001). Exp. Cell Res., 269, 230–236.

  • Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L and Khalili K . (2002b). Oncogene, 21, 4060–4064.

  • Fishman P, Bar-Yehuda S, Rath-Wolfson L, Ardon E, Barrer F, Ochaion A and Madi L . (2003). Anticancer Res., 23, 2077–2083.

  • Gessi S, Varani K, Merighi S, Morelli A, Ferrari D, Leung E, Baraldi PG, Spalluto G and Borea PA . (2001). Br. J. Pharmacol., 134, 116–126.

  • Hosokawa Y and Arnold A . (1998). Genes Chromosomes Cancer, 22, 66–71.

  • Ilyas M, Tomlinson A, Rowan M, Pignatelli WF and Bodmer E . (1997). Proc. Natl. Acad. Sci. USA, 94, 10330–10334.

  • Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM and Felsher DW . (2002). Science, 297, 63–64.

  • Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B and Pestell RG . (2001). Cytokine Growth Factor Rev., 12, 73–90.

  • Karin M, Cao Y, Greten FR and Li ZW . (2002). Nat. Rev. Cancer, 2, 301–310.

  • Kolligs FT, Bommer G and Goke B . (2002). Digestion, 66, 131–144.

  • Lovig T, Meling GI, Diep CB, Thorstensen L, Norheim Andersen S, Lothe RA and Rognum TO . (2002). Scand. J. Gastroenterol., 37, 1184–1193.

  • Madi L, Bar-Yehuda S, Barer F, Ardon E, Ochaion A and Fishman P . (2003). J. Biol. Chem., 278, 42121–42130.

  • Madrid LV, Mayo MW, Reuther JY and Baldwin AS . (2001). J. Biol. Chem., 276, 18934–18940.

  • Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S and Weinstein I . (2002). Cancer Res., 62, 3351–3355.

  • Merighi S, Varani K, Gessi S, Cattabriga E, Iannotta V, Ulouglu C, Leung E and Borea PA . (2001). Br. J. Pharmacol., 134, 1215–1226.

  • Morin JP . (1999). BioEssays, 21, 1021–1030.

  • Nguyen DC, Parsa B, Close A, Magnusson B, Crowe DL and Sinha UK . (2003). Int. J. Oncol., 22, 1285–1290.

  • Ohana G, Bar-Yehuda S, Barer F and Fishman P . (2001). J. Cell. Physiol., 186, 19–23.

  • Ohana G, Bar-Yehuda S, Arich A, Volfsson-Rat L, Madi L, Dreznick Z, Silberman D, Slosman G and Fishman P . (2003). Br. J. Cancer, 89, 1552–1558.

  • Olah ME and Stiles GL . (2000). Pharmacol. Ther., 85, 55–75.

  • Parrella P, Caballero OL, Sidransky D and Merbs SL . (2001). Invest. Ophthalmol. Vis. Sci., 42, 1679–1684.

  • Poulsen SA and Quinn RJ . (1998). Bioorg. Med. Chem., 6, 619–641.

  • Schutle G and Fredholm BB . (2002). Mol. Pharmacol., 62, 1137–1146.

  • Sears R, Nuckolls F, Haura E, Taya Y, Tamai K and Nevins JR . (2000). Genes Dev., 14, 2501–2514.

  • Suh BC, Kim TD, Lee JU, Seong JK and Kim KT . (2001). Br. J. Pharmacol., 134, 132–142.

  • Trincavelli ML, Tuscano D, Marroni M, Falleni A, Gremigni V, Ceruti S, Abbracchio MP, Jacobson KA, Cattabeni F and Martini C . (2002a). Mol. Pharmacol., 62, 1373–1384.

  • Trincavelli ML, Tuscano D, Marroni M, Klotz KN, Lucacchini A and Martini C . (2002b). Biochim. Biophys. Acta, 1591, 55–62.

  • Van Waardenburg RC, Meijer C, Burger H, Nooter K, De Vries EG, Mulder NH and De Jong S . (1997). Int. J. Cancer, 73, 544–550.

Download references

Author information

Authors and Affiliations

  1. Can-Fite Biopharma Ltd, Kiryat-Matalon, Petach-Tikva, 49170, Israel

    Pnina Fishman, Sara Bar-Yehuda, Gil Ohana, Faina Barer, Avivit Ochaion, Abigail Erlanger & Lea Madi

  2. Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel-Aviv University Sackler Faculty of Medicine, Rabin Medical Center, Petach-Tikva, Israel

    Pnina Fishman, Sara Bar-Yehuda & Gil Ohana

Authors
  1. Pnina Fishman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara Bar-Yehuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gil Ohana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Faina Barer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Avivit Ochaion
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Abigail Erlanger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lea Madi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pnina Fishman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fishman, P., Bar-Yehuda, S., Ohana, G. et al. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3β and NF-κB. Oncogene 23, 2465–2471 (2004). https://doi.org/10.1038/sj.onc.1207355

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207355

Keywords

This article is cited by

Search

Advanced search

Quick links